TITLE

The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials

AUTHOR(S)
Mallinckrodt, Craig H.; Raskin, Joel; Wohlreich, Madelaine M.; Watkin, John G.; Detke, Michael J.
PUB. DATE
January 2004
SOURCE
BMC Psychiatry;2004, Vol. 4, p26
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: A mixed-effects model repeated measures approach (MMRM) was specified as the primary analysis in the Phase III clinical trials of duloxetine for the treatment of major depressive disorder (MDD). Analysis of covariance using the last observation carried forward approach to impute missing values (LOCF_ANCOVA) was specified as a secondary analysis. Previous research has shown that MMRM and LOCF_ANCOVA yield identical endpoint results when no data are missing, while MMRM is more robust to biases from missing data and thereby provides superior control of Type I and Type II error compared with LOCF_ANCOVA. We compared results from MMRM and LOCF_ANCOVA analyses across eight clinical trials of duloxetine in order to investigate how the choice of primary analysis may influence interpretations of efficacy. Methods: Results were obtained from the eight acute-phase clinical trials that formed the basis of duloxetine's New Drug Application for the treatment of MDD. All 202 mean change analyses from the 20 rating scale total scores and subscales specified a priori in the various protocols were included in the comparisons. Results: In 166/202 comparisons (82.2%), MMRM and LOCF_ANCOVA agreed with regard to the statistical significance of the differences between duloxetine and placebo. In 25/202 cases (12.4%), MMRM yielded a significant difference when LOCF_ANCOVA did not, while in 11/202 cases (5.4%), LOCF_ANCOVA produced a significant difference when MMRM did not. In 110/202 comparisons (54.4%) the p-value from MMRM was lower than that from LOCF_ANCOVA, while in 69/202 comparisons (34.2%), the p-value from LOCF_ANCOVA was lower than that from MMRM. In the remaining 23 comparisons (11.4%), the p-values from LOCF_ANCOVA and MMRM were equal when rounded to the 3rd decimal place (usually as a result of both p-values being < .001). For the HAMD17 total score, the primary outcome in all studies, MMRM yielded 9/12 (75%) significant contrasts, compared with 6/12 (50%) for LOCF_ANCOVA. The expected success rate was 80%. Conclusions: Important differences exist between MMRM and LOCF_ANCOVA. Empirical research has clearly demonstrated the theoretical advantages of MMRM over LOCF_ANCOVA. However, interpretations regarding the efficacy of duloxetine in MDD were unaffected by the choice of analytical technique.
ACCESSION #
29323667

 

Related Articles

  • Translating comparative effectiveness of depression medications into practice by comparing the depression medication choice decision aid to usual care: study protocol for a randomized controlled trial. LeBlanc, Annie; Bodde, Amy E.; Branda, Megan E.; Yost, Kathleen J.; Herrin, Jeph; Williams, Mark D.; Shah, Nilay D.; Van Houten, Holly; Ruud, Kari L.; Pencille, Laurie J.; Montori, Victor M. // Trials;2013, Vol. 14 Issue 1, p1 

    Background: Comparative effectiveness research (CER) documents important differences in antidepressants in terms of efficacy, safety, cost, and burden to the patient. Decision aids can adapt this evidence to help patients participate in making informed choices. In turn, antidepressant therapy...

  • NICE takes fresh look at depression. Anekwe, Lilian // Pulse;3/5/2008, Vol. 68 Issue 8, p6 

    The article reports on the plan of National Prescribing Centre (NICE) to consider unpublished data on the efficacy of antidepressants before new guidance on the management of depression is published in Great Britain. According to Stephen Pilling, co-director of the National Collaborating Centre...

  • Review: an early sustained response can occur in the first and second weeks of antidepressant treatment for major depressive disorder,. Artigas, Francesc // Evidence Based Mental Health;Aug2006, Vol. 9 Issue 3, p78 

    The article comments on the study by G.I. Papakostas and colleagues on the effectiveness of antidepressants compared with placebo in the treatment of major depressive disorder. The results of eight double blind, controlled clinical trials or meta-analyses found that odds of a depressive patient...

  • Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults. Garnock-Jones, Karly P.; McCormack, Paul L. // CNS Drugs;2010, Vol. 24 Issue 9, p769 

    Escitalopram (escitalopram oxalate; Cipralex®, Lexapro®), a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD), demonstrates a highly selective and potent, dose-dependent inhibition of the human serotonin transporter, inhibiting...

  • A Meta-analysis of Factors Impacting Detection of Antidepressant Efficacy in Clinical Trials: The Importance of Academic Sites. Dunlop, Boadie W; Thase, Michael E; Wun, Chuan-Chuan; Fayyad, Rana; Guico-Pabia, Christine J; Musgnung, Jeff; Ninan, Philip T // Neuropsychopharmacology;Dec2012, Vol. 37 Issue 13, p2830 

    Variability in placebo response greatly complicates the design, conduct, and interpretation of clinical trials of antidepressant medications. To identify factors that impact detection of antidepressant-placebo differences, we conducted a meta-analysis of all relevant phase II-IV clinical trials...

  • Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features. Mallinckrodt, Craig H.; Watkin, John G.; Chaofeng Liu; Wohlreich, Madelaine M.; Raskin, Joel // BMC Psychiatry;2005, Vol. 5, p1 

    Background: The most prominent feature of melancholic depression is a near-total loss of the capacity to derive pleasure from activities or other positive stimuli. Additional symptoms can include psychomotor disturbances, anorexia, excessive guilt, and early awakening from sleep. Melancholic...

  • Epix terminates depression drug development.  // PharmaWatch: Biotechnology;May2008, Vol. 7 Issue 5, p6 

    The article reports on the discontinued clinical development of PRX-00023 by Epix Pharmaceuticals. The decision was due to lack of significant efficacy based on the recently completed phase IIb trial in patients with major depressive disorder. Epix chief executive officer (CEO) Michael Kauffman...

  • Rapid antidepressant effects of ketamine ignite drug discovery. Dolgin, Elie // Nature Medicine;Jan2013, Vol. 19 Issue 1, p8 

    The article reports on a study conducted to investigate the antidepressant effects of the ketamine. It informs that the study enrolled David Prietz, employee at a sheetmetal manufacturer in Rochester, New York, who was struggling with depression for more than 20 years. It informs that the trial...

  • Single-Dose Ketamine Associated with Rapid Improvement of Depressive Symptoms. Nierengarten, Mary Beth // MD Conference Express;Jun2014, Vol. 14 Issue 8, p17 

    Data from a randomized clinical trial show that patients with moderate to severe depressive symptoms treated with a single dose of ketamine show rapid improvement of depressive symptoms compared to patients treated with a psychoactive placebo control. This article discusses outcomes of the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics